Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Christopher Pirie
AddedMar 31, 2024
UpdatedMay 31, 2026
Christopher Pirie

Christopher Pirie

Co-Founder, Virvio

CrunchbaseLinkedIn

Christopher Pirie's Career

Virvio
Virvio

Seattle, WA, US

Co-Founder
Manus Bio
Manus Bio

Cambridge, MA, US

Co-Founder
HDT Bio
HDT Bio

Seattle, WA, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Christopher Pirie's Career

Virvio
Virvio
Angel$209k52015Seattle, WA, US
Co-Founder

Leadership at Virvio

David BakerDavid BakerCo-Founder

Similar to Virvio

Envivo BioEnvivo BioSan Mateo, CA, USMedical Devicesest. 2019Envivo BioSan Mateo, CA, US · est. 2019

Envivo Bio: Innovating non-invasive gastrointestinal microbiome sampling devices in San Carlos, CA.

Pre-Seed · $1.2M4
ViriomViriomSan Diego, CA, USHBV Treatments, HIV Treatmentsest. 2009ViriomSan Diego, CA, US · est. 2009

Viriom: A therapeutic biotech firm innovating treatments for HIV and Hepatitis B.

Series B · $35.4M200
VitriVaxVitriVaxBoulder, CO, USVaccinesest. 2017VitriVaxBoulder, CO, US · est. 2017

VitriVax develops thermostable vaccine technology, maximizing global accessibility with single-shot solutions.

Series A · $5M25
VirTech BioVirTech BioNatick, MA, USHealthcare, Researchest. 2013VirTech BioNatick, MA, US · est. 2013

VirTech Bio: Leading provider of innovative healthcare research technology.

Series B · $20.4M15
Manus Bio
Manus Bio
Seed$98.7M842011Cambridge, MA, US
Co-Founder

Recent news

North America takes the bulk of AI VC investments, despite tough political environmentTechCrunch · 2025

Leadership at Manus Bio

Byron AlsbergByron AlsbergBoard Member
Ajikumar ParayilAjikumar ParayilCo-Founder
Michael CarlosMichael CarlosBoard Member
HDT Bio
HDT Bio
Pre-Seed$70M522018Seattle, WA, US
Co-Founder

Leadership at HDT Bio

Neal ModyNeal ModyBoard Member
Steven ReedSteven ReedCo-Founder
Darrick CarterDarrick CarterCo-Founder

Similar to HDT Bio

Innovac TherapeuticsInnovac TherapeuticsCambridge, MA, USVaccinesest. 2022Innovac TherapeuticsCambridge, MA, US · est. 2022

Innovac Therapeutics: A biotech firm innovating vaccines using proprietary RNA technology.

Seed · $18M6
Chimeron BioChimeron BioPhiladelphia, PA, USRNA Drugs, Vaccinesest. 2015Chimeron BioPhiladelphia, PA, US · est. 2015

Chimeron Bio: A biotech firm pioneering in saRNA research for novel RNA drugs and vaccines.

Angel · $1.1M18
VaxEquityVaxEquityCambridge, MA, USRNA Therapeutics, Vaccinesest. 2020VaxEquityCambridge, MA, US · est. 2020

VaxEquity, a biotech firm, innovates RNA therapeutics and vaccines using saRNA for enhanced protein expression.

Pre-Seed · $700k23

Christopher Pirie's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · KakaoJB LEEJB LEECo-Founder · Kakao

People Similar to Christopher Pirie

Mike AicherMike AicherBoard Member · Roswell BiotechnologiesAnita DavidsonAnita DavidsonCo-Founder · Creative BioTherapeuticsSam ParlettSam ParlettCo-Founder · Shield BioPoriya ChintanPoriya ChintanCo-Founder · UtoboAnthony ShuberAnthony ShuberFounder · Exact SciencesChris RyanChris RyanCo-Founder · NatureWorks